不孕症药物市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024年，全球不孕症药物市场规模达40亿美元，预计2034年将以6.2%的复合年增长率成长，达到73亿美元。这一稳定成长主要源自于全球不孕症的上升，而生活方式、行为和生理因素是导致此现象的因素之一。近年来，现代生活习惯，例如高压力、不健康饮食、肥胖症盛行率上升以及延迟生育的趋势，共同导致了所有性别的生育率下降。此外，环境因素和体力活动减少也对生殖健康产生了重大影响。

随着人们对生育问题的认识不断提高，越来越多的人开始寻求医疗干预，从而推动了对有效不孕症药物的需求。随着生育问题日益普遍，医疗保健提供者越来越重视早期诊断和药物解决方案，这将继续提升市场前景。此外，生殖医学技术的进步和更广泛的可及治疗方案正在扩大市场在已开发地区和发展中地区的覆盖范围。

就药物类别而言，促性腺激素成为主导类别，2024年收入达17亿美元。这些药物在刺激排卵和提高受孕几率方面发挥关键作用，使其成为生育专家和患者的首选药物。其增强生育能力的能力使其在市场上表现强劲，并被广泛临床应用。促性腺激素在控制性卵巢刺激中的有效性及其在各种辅助生殖技术中的应用是其持续需求的关键原因。随着荷尔蒙治疗方案的不断进步，促性腺激素细分市场预计将在整个预测期内实现健康成长。

依给药途径分析，不孕症药物可分为口服、注射及外用。口服药物在2024年占据全球市场份额的58.1%，占据主导地位。其主导地位主要归功于药丸治疗的便利性，显着提高了患者的依从性。与注射剂相比，口服药物也更具成本效益且更易于给药，使其成为长期使用的理想选择。常见的口服药物，例如用于一线治疗方案的药物，被医疗保健提供者广泛用于诱导排卵。非侵入性和居家治疗方案的日益普及，进一步推动了口服药物在患者中的普及，进一步推动了该领域的成长。

按性别划分，2024年，女性群体占据了全球不孕症药物市场的绝大部分份额，预计到2034年，复合年增长率将达到6.5%。这一成长趋势的驱动力在于女性不孕症病例的不断上升，这导致对标靶治疗的需求不断增长。市场收入的很大一部分来自专门针对荷尔蒙失衡、排卵障碍和其他女性生殖健康问题的治疗。医疗意识的不断提高，加上医疗服务和生育诊所的便利性不断提高，正在鼓励更多女性寻求早期治疗，从而维持该领域的成长势头。

从分销管道来看，医院药房在2024年引领了全球不孕症药物市场，预计到2034年将达到42亿美元的市场规模。这些药房提供种类繁多的专科药物，确保患者在医院内能够可靠地取得不孕症药物。随着越来越多的患者因不孕症问题而选择医院治疗，这些机构具备在专业监督下提供必要药物的条件。不孕症负担日益加重，以及对有效、及时干预措施的需求，使得医院药房成为治疗生态系统中至关重要的组成部分。

从区域来看，北美占据全球不孕症药物市场的主导地位，2024 年的市占率为 42.6%。光是美国市场在 2024 年就达到了 15.4 亿美元，高于 2023 年的 14.6 亿美元。这一强烈的区域影响力可归因于完善的医疗基础设施、对生育相关问题的广泛认识以及先进生殖治疗手段的广泛采用。众多 FDA 批准的药物和个人化治疗方案的出现，使得美国市场特别活跃。该地区的诊所配备了先进的诊断工具和治疗方案，包括荷尔蒙疗法和促排卵剂，所有这些都有助于为寻求生育治疗的患者带来良好的治疗效果。

不孕症药物市场的竞争仍然激烈，领先的製药公司正努力透过创新和扩张来巩固其地位。辉凌製药、默克、拜耳和辉瑞等主要公司合计占了全球约60%至65%的市占率。这些公司持续投资于研发、新产品发布和全球合作伙伴关係，以保持其领先地位。同时，规模较小的区域性企业也透过提供经济高效的药物替代品并扩大其产品组合来加剧竞争。随着企业寻求提升自身能力和地域覆盖范围，併购等策略性措施在整个产业中屡见不鲜。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
  • 供应商格局
  • 每个阶段的增值
  • 影响价值链的因素
• 产业衝击力
  • 成长动力
    • 全球不孕症盛行率不断上升
    • 随着女性老化人口的增加，医疗保健意识不断提高
    • 增加不孕症药物研发的资金投入
  • 产业陷阱与挑战
    • 不孕症药物的副作用和风险
  • 市场机会
    • 辅助生殖技术（ART）的需求不断成长
    • 扩大新兴市场不孕症治疗的可近性
• 成长潜力分析
• 监管格局
• 2024年各国生育率
• 管道分析
• 未来市场趋势
• 波特的分析
• PESTEL分析

第四章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板
• 关键进展
  • 併购
  • 伙伴关係与协作
  • 新产品发布
  • 扩张计划

第五章：市场估计与预测：按药物类别，2021 - 2034 年

• 主要趋势
• 促性腺激素
• 芳香化酶抑制剂
• 选择性雌激素受体调节剂（SERM）
• 多巴胺激动剂
• 其他药物类别

第六章：市场估计与预测：按管理路线，2021 - 2034 年

• 主要趋势
• 口服
• 肠外
• 外用

第七章：市场估计与预测：依性别，2021 - 2034 年

• 主要趋势
• 女性
• 男性

第八章：市场估计与预测：按配销通路，2021 - 2034 年

• 主要趋势
• 医院药房
• 专业药局和零售药局
• 网路药局

第九章：市场估计与预测：按地区，2021 年至 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第十章：公司简介

• Abbott Laboratories
• Bayer
• Besins Healthcare
• EMD Serono (Merck KGaA)
• Ferring Pharmaceuticals
• Intas Pharmaceuticals
• Livzon
• Mankind Pharma
• Merck & Co.
• Novartis
• Organon & Co.
• Pfizer
• Sanofi
• Sun Pharmaceutical
• Teva Pharmaceutical

The Global Infertility Drugs Market was valued at USD 4 billion in 2024 and is estimated to grow at a CAGR of 6.2% to reach USD 7.3 billion by 2034. This steady growth is primarily propelled by a global rise in infertility rates, attributed to a combination of lifestyle, behavioral, and physiological factors. In recent years, modern lifestyle habits such as high stress levels, unhealthy diets, increased prevalence of obesity, and the trend of delaying parenthood have collectively contributed to declining fertility across all genders. Moreover, environmental influences and reduced physical activity are also significantly impacting reproductive health.

As awareness of fertility issues grows, more individuals are seeking medical intervention, thereby driving demand for effective infertility medications. With fertility challenges becoming increasingly common, healthcare providers are emphasizing early diagnosis and pharmaceutical solutions, which continue to enhance the market outlook. Additionally, technological improvements in reproductive medicine and a wider range of accessible treatment options are expanding the market's footprint across both developed and developing regions.

In terms of drug classes, gonadotropins emerged as a dominant category, generating USD 1.7 billion in revenue in 2024. These drugs play a pivotal role in stimulating ovulation and improving the chances of conception, which makes them a preferred choice for fertility specialists and patients alike. Their ability to enhance fertility outcomes contributes to their strong market performance and widespread clinical adoption. The effectiveness of gonadotropins in controlled ovarian stimulation and their use in various assisted reproductive techniques are key reasons behind their sustained demand. With ongoing advancements in hormone therapy protocols, the gonadotropin segment is poised to register healthy growth throughout the forecast period.

When analyzed by route of administration, infertility drugs are segmented into oral, parenteral, and topical forms. The oral segment took the lead in 2024, capturing 58.1% of the global market. Its dominance is largely due to the ease and convenience of pill-based treatments, which significantly boost patient compliance. Oral medications are also more cost-effective and easier to administer compared to injectable forms, making them ideal for long-term use. Common oral agents, such as those used in first-line treatment protocols, are widely prescribed by healthcare providers for ovulation induction. The segment growth is further fueled by the growing preference for non-invasive and home-based treatment regimens, making oral options more popular among patients.

On the basis of gender, the female segment accounted for the majority share of the global infertility drugs market in 2024 and is expected to witness a CAGR of 6.5% through 2034. This growth trend is driven by a rising incidence of female infertility cases, which has led to an increased demand for targeted therapies. A significant portion of the market's revenue comes from treatments designed specifically for hormonal imbalances, ovulation disorders, and other female reproductive health issues. Growing medical awareness, combined with better access to healthcare services and fertility clinics, is encouraging more women to seek early treatment, thereby sustaining this segment's momentum.

Based on distribution channels, hospital pharmacies led the global infertility drugs market in 2024 and are projected to generate USD 4.2 billion by 2034. These pharmacies offer a broad range of specialized medications, ensuring reliable access to fertility drugs within hospital premises. As more patients turn to hospital-based treatments for fertility concerns, these settings are well-equipped to provide the necessary medications with professional oversight. The increasing burden of infertility and the demand for effective, timely interventions have made hospital pharmacies a vital part of the treatment ecosystem.

Regionally, North America dominated the global infertility drugs market with a 42.6% share in 2024. The market in the United States alone recorded a value of USD 1.54 billion in 2024, up from USD 1.46 billion in 2023. This strong regional presence can be attributed to a well-established healthcare infrastructure, widespread awareness of fertility-related issues, and high adoption of advanced reproductive treatments. The availability of numerous FDA-approved drugs and personalized treatment plans makes the U.S. market especially dynamic. Clinics in the region are equipped with advanced diagnostic tools and treatment protocols that include hormone therapies and ovulation inducers, all contributing to favorable outcomes for patients seeking fertility care.

Competition in the infertility drugs market remains intense, with leading pharmaceutical companies striving to strengthen their positions through innovation and expansion. Major players like Ferring Pharmaceuticals, Merck KGaA, Bayer, and Pfizer collectively account for about 60% to 65% of the global market share. These companies continue to invest in R&D, new product launches, and global partnerships to maintain their leadership. In parallel, smaller regional players are increasing competition by offering cost-effective drug alternatives and expanding their product portfolios. Strategic moves such as mergers and acquisitions are common across the industry as firms seek to enhance their capabilities and geographic reach.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional
  • 2.2.2 Drug class
  • 2.2.3 Route of administration
  • 2.2.4 Gender
  • 2.2.5 Distribution channel
• 2.3 CXO perspectives: strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Value addition at each stage
  • 3.1.3 Factors affecting the value chain
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of infertility worldwide
    • 3.2.1.2 Rising healthcare awareness along with an increasing aging female population
    • 3.2.1.3 Increasing funding for infertility drugs R&D
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Side effects and risks associated with infertility drugs
  • 3.2.3 Market opportunities
    • 3.2.3.1 Growing demand for assisted reproductive technologies (ART)
    • 3.2.3.2 Expanding access to infertility treatments in emerging markets
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Fertility rates, by country, 2024
• 3.6 Pipeline analysis
• 3.7 Future market trends
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard
• 4.7 Key developments
  • 4.7.1 Merger and acquisition
  • 4.7.2 Partnership and collaboration
  • 4.7.3 New product launches
  • 4.7.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Gonadotropins
• 5.3 Aromatase inhibitors
• 5.4 Selective estrogen receptor modulators (SERMs)
• 5.5 Dopamine agonists
• 5.6 Other drug classes

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Oral
• 6.3 Parenteral
• 6.4 Topical

Chapter 7 Market Estimates and Forecast, By Gender, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Female
• 7.3 Male

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Specialty and retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Italy
  • 9.3.5 Spain
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Abbott Laboratories
• 10.2 Bayer
• 10.3 Besins Healthcare
• 10.4 EMD Serono (Merck KGaA)
• 10.5 Ferring Pharmaceuticals
• 10.6 Intas Pharmaceuticals
• 10.7 Livzon
• 10.8 Mankind Pharma
• 10.9 Merck & Co.
• 10.10 Novartis
• 10.11 Organon & Co.
• 10.12 Pfizer
• 10.13 Sanofi
• 10.14 Sun Pharmaceutical
• 10.15 Teva Pharmaceutical